The combination of good healthcare (95% of Colombian citizens have health insurance), an already strong clinical trial industry, stringent regulations issued in 2008 that requires sites to be certified by INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos) and a relatively quick and predictable approval process for launching a trial has made it a desirable clinical trial destination.
— Ronald Rosenberg, CenterWatch Weekly, April 6, 2015

Colombia offers unparalleled benefits for your first-in-man/first-in-human study

  • Competitive costs: Savings of about 30 percent or more over trials costs in the US or Europe. Today's low Colombian peso exchange rate vs the US dollar makes the country even more cost-competitive. Read more.

  • Fast and predictable national Ministry of Health regulatory pathway —about 30 days for medical devices (after local IRB/EC approval.

  • High enrollment rate: A 50-million population with universal health care coverage ensures a large patient pool of all ages.

  • Over 110 ICH/GCP-government-certified research sites with almost 30 years of experience and with the same quality and ethical standards that you would find in the U.S. and Europe.

  • FDA acceptance of clinical data from Colombia (as long as it is gathered following ICH/GCP international guidelines). Read more.

  • Fast product importation (free trade agreement with the U.S. and the E.U.).

  • Great geographical location: EST time zone, fast and direct airline connectivity from any major city.

  • Colombia has one of the four best health care systems in the world. Learn more.

  • Colombia is a top destination for medical tourism. Learn more.

  • Great healthcare infrastructure and business environment. Colombia has almost 50% of the best clinics and hospitals in Latin America. Learn more.

  • Colombia is one of the top three countries in Latin America's on the World Bank's Ease of Doing Business annual report. Learn more.

  • Highly motivated and experienced principal investigators —many of them are bilingual and trained in the US or Europe.

  • Generous government tax incentives: Life sciences startups that directly or indirectly create an entity in Colombia and invest in —or give donations to— R&D projects (e.g. clinical trials), can get a tax deduction of 175% of the amount invested and qualify for over $150 million available for grants in 2015. Read more.

  • Colombia is a Latin-American leader in volume of clinical research and receives about 40 annual clinical trials.